Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Nanobiotix-J&J Therapy Shows Promise In Tough Head And Neck Cancer

Tumor,Microenvironment,Concept,With,Cancer,Cells,,T-cells,,Nanoparticles,,Cancer,Associated

Nanobiotix SA (NASDAQ:NBTX) on Tuesday announced updated data from cohorts 1 and 2 of Study 1100 Phase 1 dose escalation and expansion trial evaluating JNJ-1900 (NBTXR3) activated by radiation therapy (RT) followed by anti-PD-1 immune checkpoint inhibitors (ICI) in patients with recurrent and/or metastatic head and neck squamous cell carcinoma that is naïve (cohort 1) or resistant (cohort 2) to prior anti-PD-1 therapy.

Study results were presented at the 2025 Annual Meeting of the American Society of Radiation Oncology.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.